Nippon Life Global Investors Americas Inc. Sells 5,550 Shares of Becton, Dickinson and Company (NYSE:BDX)

Nippon Life Global Investors Americas Inc. reduced its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 8.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,080 shares of the medical instruments supplier’s stock after selling 5,550 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Becton, Dickinson and were worth $14,858,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Accel Wealth Management raised its position in Becton, Dickinson and by 100.0% during the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 50 shares in the last quarter. Sierra Capital LLC raised its position in Becton, Dickinson and by 88.7% during the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter. Level Financial Advisors Inc. acquired a new position in shares of Becton, Dickinson and during the fourth quarter worth $26,000. Fortis Advisors LLC acquired a new position in shares of Becton, Dickinson and during the third quarter worth $27,000. Finally, Eagle Bay Advisors LLC increased its holdings in Becton, Dickinson and by 64.9% in the third quarter. Eagle Bay Advisors LLC now owns 155 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 86.58% of the company’s stock.

Shares of BDX traded up $1.16 on Friday, reaching $252.30. The company’s stock had a trading volume of 910,923 shares, compared to its average volume of 1,287,811. The company has a current ratio of 1.52, a quick ratio of 1.04 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a twelve month low of $235.13 and a twelve month high of $280.62. The stock has a market capitalization of $71.92 billion, a PE ratio of 39.79, a PEG ratio of 4.15 and a beta of 0.64. The firm has a fifty day moving average of $260.32 and a 200-day moving average of $257.72.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating the consensus estimate of $2.98 by $0.20. The firm had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $3.19 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 11.19 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a dividend yield of 1.38%. Becton, Dickinson and’s payout ratio is currently 54.89%.

In related news, EVP Betty D. Larson sold 14,374 shares of the firm’s stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Hickey sold 475 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $256.00, for a total transaction of $121,600.00. Following the completion of the transaction, the executive vice president now directly owns 3,806 shares of the company’s stock, valued at $974,336. The disclosure for this sale can be found here. Company insiders own 0.50% of the company’s stock.

A number of analysts have commented on BDX shares. Piper Sandler cut their price target on shares of Becton, Dickinson and from $265.00 to $255.00 in a research report on Thursday, May 5th. Bank of America began coverage on shares of Becton, Dickinson and in a research report on Tuesday, March 1st. They set a “neutral” rating on the stock. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Saturday, May 14th. SVB Leerink increased their price objective on shares of Becton, Dickinson and from $270.00 to $275.00 and gave the stock a “market perform” rating in a research report on Friday, February 4th. Finally, Argus increased their price objective on shares of Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $275.63.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.